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The envelope protein of Friend murine leukemia virus is modified by fatty acylation of the transmembrane (TM) protein
subunit. The labeling by [3H]palmitic acid was found to be sensitive to treatment with the reducing reagents 2-mercaptoetha-
nol and hydroxylamine, indicating the presence of a thioester linkage. Pulse-chase experiments showed that the precursor
protein can be labeled by [3H]palmitic acid prior to its cleavage into the surface and TM subunits. By using site-directed
mutagenesis, we determined that palmitoylation occurs on a cysteine residue, Cys 606, located in the transmembrane
domain. A thin-layer chromatography assay after acid hydrolysis showed that incorporated label comigrated with palmitic
acid. When another cysteine residue was introduced into the cytoplasmic tail 22 amino acids from the transmembrane
domain, no palmitoylation was observed to occur on this cysteine residue, demonstrating the importance of the position of
the cysteine residue for palmitoylation. Sequence comparison revealed that most retrovirus envelope proteins have one or
two conserved cysteine residues in their transmembrane domain. Mutations that change the palmitoylation state of the
murine leukemia virus envelope protein did not affect its transport, processing, surface expression, or cell fusion activity.
The palmitate-deficient viral envelope proteins were incorporated into virus particles, and replication of the virus in vitro
was not affected significantly by the mutation of the palmitoylation site. q 1996 Academic Press, Inc.
The envelope proteins of retroviruses mediate the including signal transduction, receptor modulation, pro-
tein localization, and lateral diffusion on cell membranesbinding of viruses to cellular receptors, as well as fusion
to the target cell membranes. In the murine leukemia (Cadwallader et al., 1994; O’Dowd et al., 1989; Alvarez et
al., 1990; Eason et al., 1994). It has been suggested thatvirus (MuLV), the envelope protein is synthesized as a
precursor which is then cleaved into two subunits, the palmitoylation may influence protein interactions with
cell membranes, and its reversibility may play a role insurface (SU) protein and the transmembrane (TM) pro-
tein, by a cellular protease (Witte and Wirth, 1979). The regulation of protein functions such as signal transduc-
tion (Resh, 1994; Casey, 1995).SU subunit mediates the binding to cellular receptors,
which may be a determinant of the viral host range. The Recent studies have indicated that palmitoylation of
viral envelope glycoproteins often occurs on the cysteineTM subunit contains three functional domains, an ecto-
domain which interacts with the SU subunit and also residues located within or close to the transmembrane
domain (Schmidt et al., 1988; Veit et al., 1989, 1991;contains a stretch of hydrophobic amino acids, the fusion
peptide, at its amino-terminus; a membrane-spanning Naeve and Williams, 1990; Rose et al., 1984; Naim et
al., 1992). Envelope glycoproteins of some retroviruses,domain which serves to anchor the envelope protein to
the cell and viral membranes; and a cytoplasmic tail (Gal- including the gp35 of Rous sarcoma virus, the gp65 of
spleen focus-forming virus, and p15E of murine leukemialaher, 1987). The envelope protein of MuLV is also exten-
sively modified posttranslationally by both N-linked and virus, have been reported to be labeled by [3H]palmitic
acid (Gebhardt et al., 1984; Srinivas et al., 1983). In thisO-linked glycosylation (Dickson et al., 1982; Pinter and
Honnen, 1988). study, we have characterized the site of palmitoylation
of the MuLV envelope protein and investigated the effectA number of viral and cellular membrane proteins have
been found to be modified by palmitoylation (Sefton and of mutations which prevented the incorporation of pal-
mitic acid into the envelope proteins.Buss, 1987; Schmidt, 1989). Palmitoylation occurs post-
translationally (Bonatti et al., 1989) and prior to transport
of the protein through the Golgi system (Schmidt and MATERIALS AND METHODS
Schlesinger, 1980). Evidence has been obtained that pro-
Cells and viruses
tein palmitoylation can affect various protein functions
HeLa T4 cells were obtained from the American Type
Culture Collection (Rockville, MD). They were maintained1 To whom correspondence and reprint requests should be ad-
dressed. in Dulbecco’s modified Eagle’s medium (DMEM) supple-
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mented with 10% bovine calf serum (GIBCO BRL, Grand pG4MOV. The codon for the cysteine residue (Cys 597 in
M-MuLV) in the transmembrane domain of the envelopeIsland, NY). A recombinant vaccinia virus (vTF7-3) ex-
pressing T7 polymerase was provided by Dr. B. Moss protein was mutated into that of a serine residue by
site-directed PCR mutagenesis, using primers 5*-GTA-(NIH, MD).
CCTACTCCAACCATACCT-3* and 5*-GACTAATCGATT-
AAGAATGGAGGGTCCGAAG-3*. The presence of thePlasmid construction and mutagenesis
mutation was confirmed by DNA sequencing and the
construct introduced back into pG4MOV by replacing theAll restriction endonucleases and enzymes used for
plasmid construction were purchased from Boehringer EcoRV–ClaI (7606–7674) fragment in pG4MOV with the
mutant DNA fragment. The resulting plasmid was desig-Mannheim Biochemicals (Indianapolis, IN). The Friend
MuLV envelope protein gene (Oliff et al., 1980) was ex- nated as pG4MOV/C597S.
cised from the plasmid p231 (provided by Dr. D. Line-
Protein expression, metabolic labeling, andmeyer) at BamHI (nucleotide 5785) and PstI (nucleotide
immunoprecipitation7884) sites and cloned into plasmid pGEM-3 (Promega,
Madison, WI) at BamHI and PstI sites so that the enve- Protein expression was carried out using the vaccinia
lope gene is under the control of the T7 promoter, desig- virus T7 system (Fuerst et al., 1986). HeLa cells were
nated as pGEMenv. MuLV envelope protein mutants seeded in 35-mm dishes, and 24 hr later they were in-
were generated through oligonucleotide-directed muta- fected by vTF7-3, a recombinant vaccinia virus express-
genesis using the M13 single-strand DNA mutagenesis ing T7 polymerase, at a m.o.i. of 10 for one and a half
method as described by Kunkel (1985). Briefly, the PstI hours. After infection, the cells were washed once with
fragment from pGEMenv was subcloned into M13mp18RF DMEM and then transfected using Lipofectin (GIBCO
(New England Biolab, Beverly, MA), and single-strand BRL, Grand Island, NY) in DMEM by plasmid DNA con-
DNA was generated and used for mutagenesis. The co- structs or control plasmid pGEM-3 as described in the
don for cysteine 606 was changed into that of serine and figure legends. After infection and transfection, the cells
the resulting construct was designated as pGEM- were labeled with either [3H]palmitic acid or [3H]leucine
envC606S. The codon for a tyrosine residue in the cyto- (NEN, Du Pont, Boston, MA). After labeling, cells were
plasmic tail (Tyr 631) was mutated into that of a cysteine washed once with DMEM and then lysed with lysis buffer
and the mutation was introduced into pGEMenvC606S (150 mM NaCl, 50 mM Tris–HCl (pH 7.5), 1 mM ethylene-
by replacing the ClaI and PstI fragment in the PGEM- diamine tetra acetate, 1% Triton X-100, 1% sodium deoxy-
envC606S. The resulting construct contains a serine co- cholate) and immunoprecipitated with appropriate anti-
don at position 606 and a cysteine codon at position 631 bodies and protein A–agarose (Pierce, Rockford, IL) at
and is designated as pGEMenvC606S/Y631C. Primers 47 overnight. Samples were prepared using either reduc-
used for mutagenesis were 5*-CGGAGCCTGTCCCTC- ing or nonreducing sample buffer (125 mM Tris–HCl (pH
TTCAGC-3* for cysteine 606 and 5*-CAAGGAGCTTCT- 7.5), 4% sodium dodecyl sulfate, 20% glycerol, and 10%
AGAGCTATT-3* for tyrosine 631. The plasmid constructs b-mercaptoethanol for 21 reducing sample buffer; non-
encoding mutant MuLV envelope proteins with an R-pep- reducing sample buffer does not contain b-mercaptoeth-
tide truncated cytoplasmic tail were constructed by the anol). All samples were heated at 957 for 5 min. before
following procedure. The codon for the alanine residue they were loaded onto SDS–PAGE gels (Laemmli, 1970).
(Ala 624) in the cytoplasmic tail was mutated into a stop
codon by site-directed mutagenesis using single-strand Hydroxylamine treatment
DNA as template. The mutation was then reintroduced
Hydroxylamine treatment of the SDS–PAGE gel wasinto the MuLV envelope gene by replacing the ClaI–PstI
carried out as described by Paige et al. (1993). Duplicatefragment from PGEMenv and pGEMenvC606S with the
samples were subjected to SDS–PAGE under the sameClaI–PstI fragment containing the truncation mutation.
conditions, and the gels were then treated by either 1 MThe primer used for this mutagenesis was 5*-CATTTG-
hydroxylamine, pH 7.5, or 1 M Tris–HCl, pH 7.5, at roomCCTAGACTACTGAG-3*. Resulting constructs are desig-
temperature overnight. All protein gels were treated withnated as pGEMenvR0 and pGEMenvR0C606S. All muta-
EnHance (NEN, Du Pont, Boston, MA) and then fluoro-tions were confirmed by DNA sequencing (Sanger et al.,
graphed using Kodak film.1977).
Plasmid pMOV3 which contains an infectious cDNA
TLC analysis of the fatty acid labeling on the MuLV
clone of Moloney murine leukemia virus was a gift from
envelope protein
Dr. S. Goff. The EcoRI fragment of pMOV which contains
the M-MuLV cDNA and some flanking cellular DNA se- To identify the fatty acid label, the MuLV envelope
protein was expressed and labeled with [3H]palmitic acidquences was subcloned into plasmid pGEM-4 (Pro-
mega), and the resulting plasmid was designated as as described above. After immunoprecipitation and
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SDS–PAGE, the proteins were blotted onto a PVDF mem- cells, which were seeded into six-well plates the previ-
ous day and grown to 80% confluence, were infectedbrane (Bio-Rad) in Towbin buffer (25 mM Tris, 192 mM
glycine, 20% methanol) using a protein blotting system with vTF7-3 and transfected with plasmid constructs con-
taining wild-type or mutant MuLV envelope genes using(Bio-Rad). The membrane was exposed to a film to locate
the position of the TM subunit, and the band was then Lipofectin (GIBCO BRL) as described above for protein
expression. At 12 hr postinfection, they were overlaidexcised and hydrolyzed in 6 N HCl at 1107 overnight. The
lipid portion was extracted by toluene and then dried with XC cells, a transformed rat cell line that can be
fused by MuLV under neutral pH conditions. Cell fusionunder vacuum. Dried samples were redissolved in 5 ml
toluene and applied onto a KC18F reverse phase chro- was monitored 6–8 hr later and photographed with a
phase contrast microscope.matography plate (Whatman). [3H]Palmitic acid and [3H]-
myristic acid (NEN, Du Pont, Boston, MA) dissolved in
toluene were used as standards. The solvent system Expression and analysis of wild-type and mutant
MuLVused for chromatography is acetic acid and acetonitrile
(1:1). After chromatography, the plate was dried and cut
Plasmids pMOV3, pG4MOV, and pG4MOV/C597Sinto 1-cm slices, and the radioactivity in each slice was
were used to transfect NIH3T3 cells by Lipofectaminecounted using a scintillation counter (Beckman) to locate
(GIBCO BRL) following the manufacturer’s procedure.the position of the radioactive label. The counts were
Seventy-two hours posttransfection, cells were split andplotted against the distance from the start point, and the
seeded into 60-mm tissue culture dishes. Sixteen hourspeak position was determined.
later, the media were collected and assayed for reverse
Biotinylation of cell surface proteins transcriptase activity, the cells were labeled with 300 mCi
Surface expression of each construct was assayed of [35S]methionine and cysteine (NEN, Du Pont, Boston,
using a surface-biotinylation assay as described by MA) in 2.5 ml of methionine and cysteine deficient Eagle’s
Spies et al. (1994). HeLa cells were seeded, infected, medium for 4 hours, and then 300 ml fetal calf serum
and transfected as described above. At 12 hr postinfec- was added. The cells were then continuously labeled for
tion, cells were starved with methionine and cysteine 8 more hours. After labeling, the media were collected,
deficient DMEM for 45 min and then pulse labeled with centrifuged at 1500 rpm for 5 min, and then passed
150 mCi of [35S]methionine and cysteine (NEN, Du Pont, through a 0.45-mm filter. A 500-ml aliquot of the media
Boston, MA) in 800 ml methionine and cysteine deficient was analyzed by immunoprecipitation and SDS–PAGE
Eagle’s medium for 45 min. After labeling, cells were directly, and 2 ml of the media was used to pellet virus
washed once with DMEM plus 10% bovine calf serum particles by centrifugation through a 20% sucrose cush-
and then chased in DMEM plus 10% bovine calf serum. ion at 32,000 rpm for 2 hr. The virus pellet was lysed
After 4 hr of chase, the cells were washed three times with lysis buffer and immunoprecipitated with antisera
with phosphate-buffered saline (PBS) and then biotinyl- against MuLV. Cells were lysed with lysis buffer and also
ated at 47 for 30 min with 0.5 mg/ml solution of sulfo- immunoprecipitated with antisera against MuLV. Sam-
succinimidyl-2-(biotinamido) ethyl -1,3-dithiopropionate ples were prepared in reducing sample buffer, heated to
(NHS-SS-Biotin, Pierce, Rockford, IL) in PBS, then lysed 957 for 5 min, and analyzed by SDS–PAGE.
with lysis buffer, and immunoprecipitated with appro-
priate antibodies and protein A–agarose at 47 overnight. RESULTS
Samples were washed twice in lysis buffer plus 0.4%
The MuLV envelope glycoproteins are palmitoylatedSDS and then split into two equal portions. One portion
was mixed with 15 ml of reducing sample buffer and Shown in Fig. 1 are schematic diagrams of the MuLV
used as a control for total cellular expression. The other envelope protein constructs used in this study. We first
portion was mixed with 20 ml of 10% SDS and heated at investigated the labeling of the wild-type MuLV envelope
957 for 15 min in order to dissociate the protein–anti- protein with [3H]palmitic acid. As shown in Fig. 2, the
body–protein A–agarose complex. Dissociated proteins MuLV envelope protein precursor gp85 and TM protein
were then dissolved in 700 ml of lysis buffer and incu- subunit p15E, but not the SU protein subunit gp70, were
bated with 10 ml of Streptavidin–agarose (Pierce, Rock-
labeled by [3H]palmitic acid, whereas all three proteins
ford, IL) for 5 hr at 47. Biotinylated samples were washed
were labeled with [3H]leucine (Fig. 2, comparing lane 1
three times with lysis buffer and mixed with 15 ml of
to lane 3). These results confirm previous studies show-
reducing sample buffer and heated at 957 for 5 min before
ing that the MuLV envelope protein can be labeled by
they were loaded onto SDS–PAGE gels.
[3H]palmitic acid and also show that the labeling is on
Fusion assay of MuLV envelope proteins the TM protein subunit.
Three types of linkages have been found for modifica-The fusion activities of MuLV envelope constructs
were determined by the following procedure. HeLa T4 tion of proteins by palmitoylation. A thioester bond to a
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FIG. 1. Schematic diagram of wild-type and mutant MuLV envelope proteins. Construction of these envelope genes is described under Materials
and Methods. Shown to the left are the designations for the envelope proteins expressed by each construct. The positions of the cysteine residue
in the transmembrane domain and the tyrosine residue in the cytoplasmic tail as well as the length of the envelope protein are also shown. Shaded
boxes represent the transmembrane domain, and black boxes represent the R-peptide.
cysteine residue or a hydroxyester bond to a serine resi-
due has been reported for most palmitoylated proteins
(Schmidt, 1989), whereas an amide bond to a lysine resi-
due has been indicated for the early region 1B 176R
protein of human adenovirus type 5 as well as some
bacterial toxins (McGlade et al., 1987; Hackett et al.,
1994; Stanley et al., 1994). In contrast to the amide bond
linkage, the thioester and hydroxyester linkages have
been reported to be sensitive to the presence of b-mer-
captoethanol in the reducing sample buffer (McGlade et
al., 1987). Moreover, the thioester bond can be distin-
guished from a hydroxyester bond by its sensitivity to
treatment by hydroxylamine (Kaufman et al., 1984).
To investigate whether the palmitic acid was attached
to the MuLV envelope proteins through a thioester bond
like other viral glycoproteins, we applied hydroxylamine
treatment to the MuLV envelope proteins labeled with
[3H]palmitic acid or [3H]leucine. After treatment with hy-
droxylamine (Fig. 3), we found that the [3H]palmitic acid
labeling of the MuLV envelope TM protein subunit was
completely removed, while the labeling with [3H]leucine
was unaffected (comparing lane 2 between hydroxyl-
amine and Tris–HCl-treated gels). This result indicates
that the labeling of MuLV envelope proteins with [3H]-
FIG. 2. Labeling of the MuLV envelope protein by [3H]palmitic acid. palmitic acid occurs via a thioester linkage and strongly
The MuLV envelope proteins were expressed and labeled as described suggests that the MuLV envelope glycoproteins are pal-
under Materials and Methods. After immunoprecipitation, samples mitoylated on cysteine residues.were prepared by mixing with nonreducing sample buffer and heated
at 957 for 5 min before SDS– PAGE. Lane 1, mock-transfected cells Localization of the site of palmitoylation
labeled with [3H]palmitic acid; lane 2, Menv labeled with [3H]palmitic
Previous studies have suggested that the palmitoyla-acid; lane 3, mock-transfected cells labeled with [3H]leucine; lane 4,
Menv labeled with [3H]leucine. tion of most viral glycoproteins occurs on cysteine resi-
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bands corresponding to the MuLV envelope protein pre-
cursor and TM protein subunit were excised, hydrolyzed,
and subjected to TLC as described under Materials and
Methods. As shown in Fig. 5, the sample from the hy-
drolyzed MuLV envelope protein gave a peak of radioac-
tivity at 7.5 cm from the origin, which corresponds to the
position of the standard [3H]palmitic acid. Under the
same condition, the standard [3H]myristic acid migrated
faster than the sample, to 9.2 cm from the origin. This
result indicates that the majority of the 3H label incorpo-
rated into the MuLV envelope proteins remains as pal-
FIG. 3. Effect of treatment with hydroxylamine. Protein samples la- mitic acid.
beled with [3H]palmitic acid or [3H]leucine were prepared by mixing
with nonreducing sample buffer and analyzed by SDS–PAGE. The pro- Kinetics of palmitoylation of the MuLV envelope
tein gels were then treated with either hydroxylamine (1 M, pH 7.5) or
proteinsTris–HCl (1 M, pH 7.5). Lane 1, mock-transfected cells labeled with
[3H]palmitic acid; lane 2, Menv labeled with [3H]palmitic acid; lane 3, In order to determine when and where the palmitoyla-
mock-transfected cells labeled with [3H]leucine; lane 4, Menv labeled
tion of the MuLV envelope glycoprotein occurs, a pulse-with [3H]leucine.
chase experiment was carried out. The results (Fig. 6)
show that the labeling of gp85 with [3H]palmitic acid was
dues within or proximal to the membrane-spanning do- detected in a 15-min pulse; however, [3H]palmitic acid
main (Schmidt et al., 1988; Veit et al., 1989, 1991; Naeve labeling of p15E could only be detected after a 30-min
and Williams, 1990; Rose et al., 1984; Naim et al., 1992). In chase and increased after 60- and 120-min chases. The
the Friend MuLV envelope protein, there is one cysteine labeling of p15E with [3H]palmitic acid was decreased
residue at position 606 in the transmembrane domain. To considerably after a 240-min chase. It is possible that
determine whether palmitoylation occurs on this cysteine after this long chase period, turnover results in replace-
residue, we used a mutant MuLV envelope protein in ment of the [3H]palmitic acid by nonradioactive palmitic
which the cysteine residue in its transmembrane domain acid as found with other palmitoylated proteins (Paige et
was changed into serine and compared its labeling with
[3H]palmitic acid with that of the wild-type envelope pro-
tein (Fig. 1). As shown in Fig. 4, the precursor protein
gp85 and the TM protein subunit p15E of the wild-type
MuLV envelope proteins were labeled by [3H]palmitic
acid, but the SU protein subunit gp70 was not (lane 1).
However, the mutant envelope proteins were not labeled
by [3H]palmitic acid (lanes 3), while they are readily la-
beled by [3H]leucine. These results show that palmitic
acid on the F-MuLV envelope protein is linked to cysteine
residue 606 in the transmembrane domain.
To investigate whether the palmitoylation can occur
on a cysteine residue placed in the cytoplasmic tail, we
constructed a plasmid, pGEMenvC606S/Y631C, which
encodes a mutant MuLV envelope protein in which the
cysteine in the transmembrane domain was changed into
a serine and a tyrosine in the cytoplasmic tail 22 amino
acids away from the transmembrane domain was
changed into a cysteine. As shown in Fig. 4, this newly
introduced cysteine residue was not found to be labeled
by [3H]palmitic acid (lane 4). These results indicate that
the location of the cysteine residue is important for palmi- FIG. 4. Lack of [3H]palmitate labeling of the MuLV envelope protein
toylation. cysteine mutants. HeLa T4 cells were infected with vTF7-3 followed by
transfection with plasmid constructs containing the wild-type or mutant
Identification of the incorporated label as palmitic MuLV envelope gene. At 12 hr postinfection, cells were labeled with
either 50 mCi of [3H]leucine or 500 mCi of [3H]palmitic acid for 4.5 hr.acid
Protein samples were prepared using nonreducing sample buffer and
To identify the incorporated fatty acid label, we used analyzed by SDS–PAGE. Lane 1, mock-transfected cells; lane 2, Menv;
lane 3, MenvC606S; lane 4 , MenvC606S/Y631C.a thin-layer chromatography (TLC) assay. The protein
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lope protein does not affect its expression, processing,
or transport to the plasma membrane.
In MuLV, the envelope protein is further processed by
the viral protease which cleaves the C-terminal 16 amino
acids, the R-peptide, from the cytoplasmic tail (Green et
al., 1981). Recent studies have reported that truncation
of the R-peptide in the cytoplasmic tail greatly increased
the fusion activity of the MuLV envelope protein (Rein et
al., 1994; Ragheb and Anderson, 1994; Yang and Com-
pans, 1996). To determine whether the palmitoylation
state of the envelope protein affects its fusion activity,
we introduced a stop codon into the wild-type and mutant
MuLV envelope genes. The new constructs are desig-
nated as pGEMenvR- and pGEMenvR-C606S, and the
MuLV envelope proteins expressed from these con-
structs contain an R-peptide truncated cytoplasmic tail
(Fig. 1). We compared the fusion activities of these wild-
type and mutant MuLV envelope proteins. As shown inFIG. 5. Thin-layer chromatography analysis of [3H]palmitic acid-la-
Fig. 8, similar levels of cell fusion were observed forbeled MuLV envelope proteins. A hydrolyzate of [3H]palmitic acid-la-
beled MuLV envelope proteins was prepared as described under Mate- either wild-type or mutant envelope proteins with trunca-
rials and Methods and analyzed by chromatography on a C18 reverse tion of the R-peptide in the cytoplasmic tail (comparing
TLC plate. The TLC plate was cut into slices, and the radioactivity in e and f), whereas no fusion was observed for wild-type
each slice was counted. The counts were then plotted against the
or mutant envelope proteins with full-length cytoplasmicdistance from the origin. Arrows indicate the distance that [3H]palmitic
acid (arrow p) and [3H]myristic acid (arrow m) migrated from the origin.
al., 1993). However, we cannot rule out the possibility
that the decrease is due to the instability of p15E. These
results indicate that palmitoylation of the MuLV envelope
protein occurs before the processing of gp85 into gp70
and p15E. Studies on the transport and processing of
retrovirus envelope proteins have indicated that the
cleavage occurs in the cis-Golgi system (Willey et al.,
1988; Kozarsky et al., 1989; Hallenberger et al., 1992).
Therefore, it is likely that palmitoylation of the MuLV en-
velope protein occurs before the envelope proteins exit
from the cis-Golgi complex.
The palmitoylation state of the MuLV envelope
protein does not affect its transport or cell fusion
activities
The results presented above demonstrate that the
MuLV envelope proteins are palmitoylated and that the
palmitoylation of the MuLV envelope protein occurs on
the cysteine residues in its transmembrane domain. We
further investigated the secretion and surface expression
of wild-type and mutant MuLV envelope proteins using
FIG. 6. Pulse-chase analysis of labeling with [3H]palmitic acid. The
pulse-chase labeling and a surface biotinylation assay MuLV envelope proteins were expressed in HeLa T4 cells using the
(Fig. 7). Comparing lanes 2–5, a similar level of expres- vaccinia virus T7 system. At 12 hr postinfection, cells were pulse la-
beled with [3H]palmitic acid and chased in DMEM plus 10% bovinesion was observed for the wild-type and mutant envelope
calf serum for different intervals as described under Materials andproteins. The level of secretion of gp70 also showed no
Methods. Lane 1, mock-transfected cells, continuous labeling for 4.5significant differences among these constructs (superna-
hr; lanes 2–7, Menv; lane 2, 15-min pulse; lane 3, 15-min pulse and
tant). Surface expression as detected by the biotinylation 30-min chase; lane 4, 15-min pulse and 60-min chase; lane 5, 15-min
assay was not affected by these mutations either (sur- pulse and 120-min chase; lane 6, 15-min pulse and 240-min chase;
lane 7, Menv continuous labeling for 4.5 hr.face). Therefore, the palmitoylation state of MuLV enve-
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FIG. 7. Secretion and surface expression of mutant and wild-type MuLV envelope proteins. Surface expression of the MuLV envelope proteins
were detected by cell surface biotinylation. Protein samples were prepared as described under Materials and Methods and analyzed by SDS–
PAGE. Lane 1, mock-transfected cells; lane 2, Menv; lane 3, MenvC606S; lane 4, MenvC606S/Y631C; lane 5, MenvR0; lane 6, MenvR0C606S.
tails (comparing b, c, and d). These results indicate that the MuLV envelope protein does not significantly affect
virus replication in cell cultures.the palmitoylation state does not affect the fusion activity
of the MuLV envelope protein.
DISCUSSION
Palmitate-deficient MuLV envelope proteins are
In this study, we present evidence that the MuLV enve-incorporated into infectious virus particles
lope protein is palmitoylated on a specific cysteine resi-
due in the transmembrane domain. The fact that the pal-To investigate whether palmitoylation of the envelope
protein could have an effect on virus replication, we con- mitate label is sensitive to reducing reagents, as shown
by treatment with reducing sample buffer or hydroxyl-structed a mutant M-MuLV env gene in which the codon
for the cysteine residue in the transmembrane domain, amine, indicates that the attachment of the palmitic acid
is through a thioester linkage to a cysteine residue.cysteine 597, was changed into a serine residue codon
and introduced the mutant M-MuLV env gene into an Pulse-chase experiments indicate that palmitoylation of
the MuLV envelope protein occurs posttranslationallyinfectious M-MuLV cDNA clone. Wild-type and mutant
cDNAs were used to transfect NIH3T3 cells and analyzed prior to its cleavage into the SU and TM subunits. By
using site-directed mutants, we determined that the sitefor virus production by metabolic labeling with [35S]-
methionine/cysteine and immunoprecipitation. As shown of palmitoylation of the MuLV (Friend strain) envelope
protein is a cysteine residue, cysteine 606, in its trans-in Fig. 9, viral proteins were efficiently synthesized and
processed. The incorporation of the mutant envelope membrane domain. In studying the possible functions
of palmitoylation, we found that mutations in the MuLVprotein into released virus particles was reduced by
about 30% as compared to the wild-type envelope protein envelope protein that change its palmitoylation state do
not affect its expression, transport, or fusion activity. Weas determined by densitometry, while similar amounts of
gag proteins were found in the pelleted virus particles further found that mutation of the palmitoylated cysteine
residue into a serine residue did not significantly affect(comparing lane 2 to lane 3 of the virus pellet). However,
the cellular level of the mutant Env protein was similarly virus infectivity.
In the vast majority of cellular and viral transmembranereduced by about 30%, possibly due to a difference in
stability of the palmitate-deficient envelope protein. The proteins which have been reported to be palmitoylated,
the site of palmitoylation appears to be within or close toreplication kinetics and infectivity were not significantly
affected by the cysteine to serine mutation as assayed the membrane-spanning domain (Schmidt, 1989), usually
less than six amino acids away from the membrane-by RT assay and XC cell plaque assay (data not shown).
Therefore, these results indicate that palmitoylation of spanning domain. For example, the CD4 molecule, the
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FIG. 8. Cell fusion activities of wild-type and mutant MuLV envelope proteins. HeLa T4 cells were infected with vTF7-3 followed by transfection
with plasmid constructs containing the wild-type or mutant MuLV envelope gene. At 12 hr postinfection, the infected and transfected HeLa T4 cells
were overlaid with XC cells. Cell fusion was monitored and photographed with a phase contrast microscope. (a) Mock-transfected cells; (b) Menv;
(c) MenvC606S; (d) MenvC606S/Y631C; (e) MenvR0; (f) EMenvR0C606S.
cellular receptor for HIV, contains five cysteine residues
in its cytoplasmic tail, but only the two membrane proxi-
mal cysteine residues are palmitoylated (Crise and Rose,
1992). The other three cysteine residues which are fur-
ther away from the membrane-spanning domain are not
palmitoylated. We also found in this study that when a
cysteine residue was introduced into the MuLV envelope
protein cytoplasmic tail 22 amino acids from the trans-
membrane domain, palmitoylation did not occur on this
cysteine residue, suggesting that membrane association
is required for palmitoylation. Cytoplasmic proteins are
usually palmitoylated on cysteine residues located in re-
gions that associate with the plasma membranes (Resh,FIG. 9. Characterization of viral protein synthesis assembly wild-type
and palmitate-deficient murine leukemia viruses. NIH3T3 cells were 1994). However, it is uncertain whether palmitoylation
transfected with plasmids pMOV3, pG4MOV, and pG4MOVC597S using can only occur when the protein is in close contact with
Lipofectamine. Cells were labeled with [35S]methionine/cysteine and cell membrane or whether there is some sequence motif
protein samples were prepared as described under Materials and
that is recognized for palmitoylation which then promotesMethods and analyzed by SDS –PAGE. Lane 1, no transfection; lane
protein interactions with the cell membrane.2, transfected with plasmid pG4MOVC597S; lane 3, transfected with
plasmid pG4MOV; lane 4, transfected with plasmid pMOV3. Although the precise functions for the palmitoylation of
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many cellular and viral proteins are presently unknown, Simpson and Lamb, 1992). It has also been reported that
mutation of a cysteine residue (Cys 560) in the influenzaseveral studies have indicated that the addition of pal-
mitic acid may enhance protein association with cellular virus hemagglutinin cytoplasmic tail changed the sorting
of the hemagglutinin from the apical to the basolateralmembranes (James and Olson, 1990; Mumby et al., 1994;
Wedegaertner et al., 1993). Rhodopsin is a type III mem- surface in polarized epithelial cells (Brewer and Roth,
1991). Whether palmitoylation on this cysteine residuebrane protein with six hydrophobic membrane-spanning
domains which are thought to form three cytoplasmic played any role in this change of membrane targeting of
the influenza virus hemagglutinin is not known. There isloops. Koenig et al. (1989) have proposed that the pres-
ence of palmitic acid in the cytoplasmic domain of rho- also a report that treating cells with hydroxylamine, which
could remove palmitic acid acylation, inhibits the fusiondopsin allows the protein to form an additional cyto-
plasmic loop, mediated by the insertion of palmitic acid activity of the influenza hemagglutinin and the Semliki
Forest virus envelope protein (Schmidt and Lambrecht,in the cell membrane. Morrison and Portner (1991) have
reported that depalmitoylation of rhodopsin alters its abil- 1985). However, whether the reduction in fusion activity
resulted from the elimination of palmitoylation is not cer-ity to activate transduction, a finding which they sug-
gested may be due to an increased mobility in the cell tain. Studies with the influenza virus M2 protein have
indicated that mutation of the palmitoylated cysteine resi-membrane in the absence of palmitic acid. Another ex-
ample of the possible role of palmitoylation is the de- due resulted in destabilization of the M2 oligomers, al-
though the exact role of palmitoylation was not estab-creased ability of a nonpalmitoylated b2-adrenergic re-
ceptor to mediate isoproterenol stimulation of adenylyl lished (Sugrue et al., 1990).
In accordance with results from other studies whichcyclase, an effect apparently caused by the loss of a
crucial association of the palmitoylated protein cyto- reported that mutations altering protein palmitoylation
usually do not cause defects in protein transport or sur-plasmic domain with the plasma membrane (O’Dowd et
al., 1989). Recent studies by Cadwallader et al. (1994) face expression (Crise and Rose, 1992; Naim et al., 1992),
we observed that palmitoylation of the MuLV envelopeindicated that the palmitoylation of the Ras protein can
contribute to localization of N-terminally myristoylated glycoprotein did not affect its expression, transport, or
cell fusion activity. We also observed that palmitoylationRas protein on the plasma membrane.
Although the first proteins that were found to be palmi- of the MuLV envelope protein was not required for its
incorporation into virus particles. Sequence comparisontoylated were viral envelope proteins, not much is known
about the function of the palmitoylation of these glycopro- reveals that most retrovirus envelope proteins (except
lentiviruses) contain one or two cysteine residues in theteins. Studies with alphaviruses indicated that palmitoyl-
ation of the envelope protein E2 is important for virus transmembrane domain, and usually these cysteine resi-
dues are highly conserved within each virus species (asreplication (Ivanova and Schlesinger, 1993). In studies
with influenza virus hemagglutinin, Zurcher et al. (1994) shown in Table 1). Retroviruses are notorious for their
high mutation rates during replication. The presence ofreported that mutations of the palmitoylated cysteine res-
idues in its cytoplasmic tail affected virus formation and a conserved cysteine residue in the transmembrane do-
main implies that it may be important for virus replication.infectivity. However, other groups have obtained evi-
dence that palmitoylation of the influenza virus envelope Although our results indicated that palmitoylation of the
MuLV envelope protein does not significantly affect virusglycoprotein did not affect its infectivity (Naim et al., 1992;
TABLE 1
Examples of Cysteine Residues Present in the Transmembrane Domains of Retrovirus Envelope Proteins
Amino acid sequence of
Virus group Virus the transmembrane domain
Avian C type Rous sarcoma virus GLLLGLVVILLLVVCLPCLLQIVCGSI
Mammalian C type Murine leukemia virus FTTLISTIMGPLIILLLILLFGPCILN
Feline leukemia virus FTTLISSIMGPLLILLLILLFGPCILN
B type Mouse mammary tumor virus YFIFIGVGALLLVIVLMIFPIVFQCLA
D type Mason–Pfizer virus GFLPYVMLLGPLLCLLLVLSFGPIIFN
HTLV–BLV Human T-cell leukemia virus type I TGITLVALLLLVILAGPCIL
Human T-cell leukemia virus type II ALQTGITILALLLLVILFGPCIL
Bovine leukemia virus VLSLFLLALFLLFLAPCLI
Amino acid sequences of the postulated transmembrane domain for each retrovirus envelope protein were obtained from data in GenBank.
The cysteine residues are shown in bold.
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James, G., and Olson, E. N. (1990). Fatty acylated proteins as compo-replication in vitro, it will be interesting to further investi-
nents of intracellular signaling pathways. Biochemistry 29, 2623–gate the possible role that palmitoylation of the retrovirus
2634.
envelope proteins plays in modulating the pathogenesis Kaufman, J. F., Krangel, M. S., and Strominger, J. L. (1984). Cysteines
of the viruses. in the transmembrane region of major histocompatibility complex
antigens are fatty acylated via thioester bonds. J. Biol. Chem. 259,
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